CoChat

Optimizing phase II of drug development for disease‐modifying compounds

Cummings, Jeffrey L. · 2008 · Alzheimer's & Dementia
Cited by 31

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Phase II proof of concept (POC) (IIa) and dose‐finding (IIb) studies represent major challenges in drug development. Prolonged development times delay effective therapies from reaching patients in need and adversely affect industry goals of decreasing time to market. Biomarkers including magnetic resonance imaging, cerebrospinal fluid tau and amyloid β, and amyloid positron emission tomography have been considered as alternative outcomes to clinical measures. None of these is yet validated. Population enrichment is another possible solution to POC studies. More rapid progression to prespecified milestones can be achieved by enriching the population with risk factors. Conclusions based on enriched populations must be extrapolated with caution. Clinical measures with greater sensitivity than standard trial instruments might represent another strategy applicable to POC studies. Adaptive dose‐response designs are being considered as a means of shortening phase IIb studies and creating a seamless interface with phase III. None of these strategies have been validated in a successful drug development program; all have some promise for reforming phase II and answering the central question of “how much information is sufficient to proceed to phase III without excessive risk for failure?”

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2007.10.002

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 31

Metadata

Authors
Cummings, J. L.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2008-01
Volume
4
Issue
1S1
Pages
S15-20
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2166949035
Cited by
31
References
7
FWCI
1.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing phase II of drug development for disease‐modifying compounds. https://app.cochat.ai/papers/10.1016/j.jalz.2007.10.002
The paper
Cummings, J. L. (2008). Optimizing phase II of drug development for disease‐modifying compounds. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2007.10.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.